4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
申请人:Confluence Life Sciences Inc.
公开号:US20150203499A1
公开(公告)日:2015-07-23
The present disclosure provides 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), providing a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R
1
and R
2
are as defined in the detailed description.
本公开提供4-烷氧基/芳氧基-5-取代-吡咯蒽嘧啶化合物、药学上可接受的盐、溶剂和由式(I)所包含的化合物组成的制药组合物,为患有疾病情况的受试者提供治疗益处,特别是癌症,其中R1和R2如详细说明中所定义。